Abstract
Drug discovery is costly and time-consuming, but it will become easier and simpler if a drug could be developed from an old one with well-documented investigations associated with pharmacology, pharmacokinetics, toxicology and clinical safety. In terms of hematological malignancies, several successful drugs have been discovered and developed from old ones such as arsenic trioxide for acute promyelocytic leukemia and thalidomide for multiple myeloma. In this review, we discussed the latest advancement in exploring old drugs for the treatment of hematological malignancies.
Keywords: Drug repositioning, drug discovery, old drug, hematological malignancy, drug, arsenic trioxide, pharmacological, therapeutic, dysfunction, methotrexate, rheumatoid arthritis, hematological malignancies
Current Medicinal Chemistry
Title: Exploring Old Drugs for the Treatment of Hematological Malignancies
Volume: 18 Issue: 10
Author(s): F. Gan, B. Cao, D. Wu, Z. Chen, T. Hou and X. Mao
Affiliation:
Keywords: Drug repositioning, drug discovery, old drug, hematological malignancy, drug, arsenic trioxide, pharmacological, therapeutic, dysfunction, methotrexate, rheumatoid arthritis, hematological malignancies
Abstract: Drug discovery is costly and time-consuming, but it will become easier and simpler if a drug could be developed from an old one with well-documented investigations associated with pharmacology, pharmacokinetics, toxicology and clinical safety. In terms of hematological malignancies, several successful drugs have been discovered and developed from old ones such as arsenic trioxide for acute promyelocytic leukemia and thalidomide for multiple myeloma. In this review, we discussed the latest advancement in exploring old drugs for the treatment of hematological malignancies.
Export Options
About this article
Cite this article as:
Gan F., Cao B., Wu D., Chen Z., Hou T. and Mao X., Exploring Old Drugs for the Treatment of Hematological Malignancies, Current Medicinal Chemistry 2011; 18 (10) . https://dx.doi.org/10.2174/092986711795328427
DOI https://dx.doi.org/10.2174/092986711795328427 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Biodistribution and Tumor Targeting of Indium and Iodine-labeled Shiga Toxin B-Subunit
Current Radiopharmaceuticals Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update
Current Drug Metabolism Antiangiogenic Therapeutic Approaches in Multiple Myeloma
Current Cancer Drug Targets New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Synthesis, Characterization and Evaluation of Cytotoxicity of New Aminophosphonic Acid Diesters in Human Leukemia Cells
Letters in Drug Design & Discovery Anthracyclines Still Prove Effective in Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Human Immunodeficiency Virus-Associated Malignancies: A Therapeutic Update
Current HIV Research Monoclonal Antibodies in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction
Mini-Reviews in Medicinal Chemistry Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide
Current Cancer Drug Targets DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Current Drug Targets Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets